© Parkinson’s UK, July 2019. Parkinson’s is the operating name of the Parkinson’s Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554)

Parkinson's UK

Jan

2018

Mar 2018

Jul

 2019

Aug 2019

Oct

2019

Phase II trial of cannabidiol for Parkinson's psychosis - King's College London 

£1.2 million over 42 months (currently active)

​A 6-week pilot and 12-week double, blind placebo-controlled trial to provide preliminary evidence for the safety and efficacy of cannabidiol (CBD) capsules for the treatment of Parkinson's-related psychosis.

Novel mitochondrial rescue compounds - University of Sheffield 

£98,000 over 12 months (currently active)

Screening and in vitro testing programme to identify compounds that rescue mitochondrial function with reduced off-target effects.

Novel mPTP inhibitors - NRG Therapeutics

£1 million over 12 months (currently active)

A preclinical programme to discover and develop a potential drug that could safeguard the dopaminergic cells damaged by Parkinson's and slow down the progression of the condition.

Novel gene transcription modulators - Eurofins Selcia Drug Discovery

£2.5 million over 24 months (currently active)

A drug discovery and development programme to create molecules that increase the activity of genes  to increase dopamine synthesis and boost the production of neuroprotective proteins.

Serotonin 5-HT1A receptor agonist, NLX-112 - Neurolixis

£780,000 over 15 months

This project supported the final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.

Mar 2017

Oct 2012

Novel Nrf2-KEAP1 inhibitors - Keapstone Therapeutics Limited

£2.3 million over 28 months

A drug discovery and development programme that developed and optimised novel inhibitors of the interaction between NFE2-related factor 2 (Nrf2) and Kelch-like ECH associated protein 1 (KEAP1).

Glial cell line-derived neurotrophic factor - Medgenesis Therapeutics Inc.

£2.5 million over 62 months

A placebo-controlled, randomised, double-blind trial that assessed the safety and efficacy of intermittent bilateral intraputamenal glial cell line-derived neurotrophic factor (GDNF) infusions administered via convection enhanced delivery (CED) in subjects with Parkinson’s disease.